SMFR News and Press, Sema4 Holdings Corp. From 01/31/22

Technology is evolving faster than our brains can keep up. From wearable technology to smart homes to drones, everything we know, and love is being “disrupted” by the Internet of Things (IoT). Today a small company called GBT Technologies Inc. (OTC US: GTCH) develops A...

Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and forme...

STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced preliminary revenue (unaudited) for the fourth quarter and fiscal year ended December 31, 2021 and provided a business update. ...

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt, PhD, Founder and Chief Executive Officer, and Isaac Ro , Chief Financial Officer, will participate at the ...

The following slide deck was published by Sema4 Holdings Corp. in conjunction with their 2021 Q3 earnings call. For further details see: Sema4 Holdings Corp. 2021 Q3 - Results - Earnings Call Presentation

Sema4 Holdings Corp. (SMFR) Q3 2021 Earnings Conference Call November 16, 2021, 4:30 PM ET Company Participants Eric Schadt – Founder and Chief Executive Officer Joel Kaufman – VP Finance & Corporate Development Isaac Ro – Chief Financial Officer Conference Call Parti...

Corvex Management takes new positions in Sema4 Holdings (NASDAQ:SMFR) with 4.5M shares, SomaLogic (NASDAQ:SLGC) with 2.5M shares, Uber (NYSE:UBER) with 1.23M shares and U.S. Foods (NYSE:USFD) with 1.02M shares, according to its most recent 13-F filing. Boosts stake in Zynga (NASDAQ:ZNGA) to m...

Sema4 (NASDAQ:SMFR): Q3 GAAP EPS of $0.15. Revenue of $43.18M (+11.8% Y/Y) Press Release For further details see: Sema4 reports Q3 results

36% increase in test volume (excluding COVID-19 tests) compared to the same period last year 17% growth in revenue (excluding COVID-19 tests) compared to the same period last year Full year 2021 total revenue guidance range of $201 million to $204 million Sema4 t...

STAMFORD, Conn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, recently published two studies demonstrating the utility of machine learning to predict clinical outcomes for postpartum hemorrhage (PPH). The s...